BRIEF published on 06/16/2026 at 21:21, 1 month 25 days ago Medincell: Key Results and Initiatives for 2025-2026 Innovation Treasury R&D Royalties Medincell
PRESS RELEASE published on 06/16/2026 at 21:16, 1 month 25 days ago Informations privilégiées / Communiqué sur comptes, résultats Medincell publie ses résultats financiers annuels consolidés pour l'exercice 2025-2026, mettant en avant la solidité opérationnelle et la transition vers un modèle reposant sur l'innovation et les revenus récurrents Résultats Financiers Innovation Revenus Récurrents Medincell Exercice 2025-2026
BRIEF published on 05/21/2026 at 19:29, 2 months 21 days ago L'EMA accepte la demande de Teva pour un traitement de la schizophrénie à action prolongée Traitement De La Schizophrénie Teva Pharmaceuticals Approbation De L'EMA Olanzapine Injectable Formule À Action Prolongée
BRIEF published on 05/21/2026 at 19:29, 2 months 21 days ago EMA Accepts Teva's Application for Long-Acting Schizophrenia Treatment Schizophrenia Treatment Teva Pharmaceuticals EMA Approval Olanzapine Injectable Long-acting Formulation
PRESS RELEASE published on 05/21/2026 at 19:24, 2 months 21 days ago Informations privilégiées / Autres communiqués L'EMA accepte le dossier de demande de mise sur le marché de l'Olanzapine LAI par Teva pour le traitement de la schizophrénie. Technologie de libération prolongée SteadyTeq(TM) utilisée Schizophrénie Teva EMA Olanzapine LAI SteadyTeq
PRESS RELEASE published on 05/21/2026 at 19:24, 2 months 21 days ago Inside Information / Other news releases European Medicines Agency accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable to treat schizophrenia in adults. Teva and Medincell announce EMA acceptance for innovative treatment option Schizophrenia Medincell Olanzapine Teva EMA
BRIEF published on 04/29/2026 at 13:44, 3 months 13 days ago Croissance impressionnante des ventes de UZEDY® au T1 2026 Schizophrénie Medincell Teva Pharmaceuticals UZEDY® Ventes T1 2026
BRIEF published on 04/29/2026 at 13:44, 3 months 13 days ago UZEDY® Q1 2026 Sales Surge by 62% FDA Approvals Olanzapine LAI UZEDY® Sales Teva Partnership Medincell Growth
BRIEF published on 04/29/2026 at 13:44, 3 months 13 days ago Impressive sales growth for UZEDY® in Q1 2026 Schizophrenia Medincell Teva Pharmaceuticals UZEDY® Q1 2026 Sales
BRIEF published on 04/29/2026 at 13:44, 3 months 13 days ago Les ventes d'UZEDY® au premier trimestre 2026 devraient bondir de 62 %. Olanzapine LAI Ventes UZEDY® Partenariat Avec Teva Approbations De La FDA Croissance De Medincell
Published on 08/12/2026 at 15:42, 2 hours 51 minutes ago Critical Elements 10,000-Meter Summer Drill Program at Rose West Resumes with Positive Results
Published on 08/12/2026 at 15:42, 2 hours 51 minutes ago Critical Elements redémarre son programme de forage estival de 10 000 mètres à Rose Ouest avec des résultats positifs
Published on 08/12/2026 at 15:00, 3 hours 33 minutes ago Karbon-X and Core Energy Sign Letter of Intent to Explore Commercial EV Charging Infrastructure in South America
Published on 08/12/2026 at 14:45, 3 hours 48 minutes ago Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Published on 08/12/2026 at 18:17, 16 minutes ago EQS-Adhoc: Gateway Real Estate AG resolves segment change from the regulated market (Prime Standard) to the Scale segment of the open market (Freiverkehr) on the Frankfurt Stock Exchange
Published on 08/12/2026 at 18:15, 18 minutes ago Shelly Group Delivers Strong Revenue and Earnings Growth in the First Six Months of 2026
Published on 08/12/2026 at 18:00, 33 minutes ago ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 31.07.26
Published on 08/11/2026 at 17:45, 1 day ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 1 day ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 2 days ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 days ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
